Automated Breast Ultrasound Systems (ABUS) Market Size, Share Global Analysis Report, 2026-2034

Industry Insights

[235+ Pages Report] According to Facts & Factors, the global automated breast ultrasound systems (ABUS) market size was estimated at USD 2.5 billion in 2025 and is expected to reach USD 10.1 billion by the end of 2034. The automated breast ultrasound systems (ABUS) industry is anticipated to grow by a CAGR of 16.7% between 2026 and 2034. The automated breast ultrasound systems (ABUS) Market is driven by the rising prevalence of breast cancer, technological advancements in AI-integrated 3D imaging, increasing awareness for early detection especially in dense breast tissue, and supportive government screening programs worldwide.

Market Overview

Automated breast ultrasound systems (ABUS) represent a revolutionary imaging technology designed to provide automated, operator-independent three-dimensional scans of the entire breast. Unlike traditional handheld ultrasound, ABUS captures consistent volumetric images that enhance the detection of lesions hidden in dense breast tissue where mammography often falls short. This non-invasive, radiation-free modality serves as a critical supplemental tool for breast cancer screening and diagnosis, offering improved accuracy, patient comfort, and standardized results across diverse clinical settings. The technology integrates advanced software for lesion visualization and is increasingly enhanced by artificial intelligence to support radiologists in faster and more precise interpretations.

Key Insights

• As per the analysis shared by our research analyst, the automated breast ultrasound systems (ABUS) market is projected to grow at a CAGR of 16.7% during the forecast period 2026-2034.
• In terms of revenue, the market size was valued at USD 2.5 billion in 2025 and is projected to reach USD 10.1 billion by 2034.
• The market is driven by the rising prevalence of breast cancer, advancements in AI-integrated imaging technologies, and growing awareness for early detection in women with dense breast tissue.
• Based on the product type segment, the Automated Breast Ultrasound System (ABUS) subsegment dominated with approximately 63% market share because it delivers standardized 3D volumetric imaging with reduced operator dependency and superior lesion detection in dense breasts.
• Based on the application segment, the Breast Cancer Screening subsegment dominated with the largest share due to its proven efficacy as a supplemental tool to mammography for high-risk and dense-breast patients, driving higher adoption in preventive care.
• Based on the end-user segment, the Hospitals subsegment dominated with approximately 45% market share owing to advanced infrastructure, high patient volumes, integrated screening programs, and availability of trained radiologists for comprehensive multimodal imaging.
• Based on the region segment, North America dominated with approximately 38% market share because of high breast cancer awareness, favorable reimbursement policies, advanced healthcare facilities, and strong regulatory support for supplemental screening technologies.

Growth Drivers

• Rising Breast Cancer Prevalence and AI-Driven Technological Advancements

The surge in global breast cancer incidence, combined with the limitations of traditional mammography in dense breast tissue affecting over 40% of women, has created urgent demand for supplementary imaging solutions like ABUS that deliver operator-independent 3D scans and enhanced lesion visibility. Government initiatives, national screening programs, and increased reimbursement coverage in developed markets have further accelerated adoption by making the technology more accessible to both hospitals and outpatient facilities.

Integration of artificial intelligence for automated lesion detection, risk prediction, and workflow optimization has transformed ABUS from a diagnostic aid into a predictive tool, reducing reading time and inter-observer variability while improving early-stage cancer detection rates significantly. These advancements, along with compact and mobile system designs, are expanding reach into underserved regions and outpatient settings, fueling sustained double-digit market expansion through 2034.

Restraints

• High Capital Costs and Shortage of Skilled Personnel

The substantial upfront investment required for ABUS equipment, along with ongoing maintenance and software upgrade expenses, restricts adoption primarily to large hospitals and well-funded diagnostic centers, leaving smaller clinics and emerging markets underserved. Limited reimbursement in certain regions and the perception of ABUS as an add-on rather than standalone modality further slow penetration among cost-sensitive healthcare providers.

In many developing countries, the acute shortage of trained radiologists and sonographers capable of interpreting complex 3D volumetric datasets creates operational bottlenecks, delaying full utilization of installed systems and hindering broader market acceptance despite clear clinical benefits.

Opportunities

• AI Integration and Expansion into Emerging Markets

Rapid incorporation of AI, machine learning, and radiomics into ABUS platforms opens new avenues for personalized screening, real-time decision support, and telemedicine-enabled remote diagnostics, particularly benefiting rural and resource-limited settings through cloud-based analysis. Public-private partnerships and mobile screening units are poised to bridge access gaps in Asia Pacific and Latin America where aging populations and rising breast cancer awareness are creating untapped demand.

Growing focus on value-based healthcare and preventive medicine encourages healthcare systems to adopt ABUS as part of comprehensive breast health programs, while collaborations between device manufacturers and AI software firms are expected to introduce cost-effective, portable solutions that accelerate market penetration globally.

Challenges

• Data Management and Regulatory Hurdles

Handling large volumetric datasets generated by ABUS requires robust IT infrastructure, secure storage solutions, and integration with existing PACS/EHR systems, posing technical and cybersecurity challenges for many facilities. Inconsistent image quality due to patient movement or anatomical variations can occasionally lead to diagnostic uncertainty, necessitating additional training and quality assurance protocols.

Regulatory pathways for AI-enhanced features remain complex across regions, while proving long-term clinical efficacy as a standalone screening tool continues to demand extensive multi-center trials, slowing widespread insurance coverage and adoption in conservative healthcare systems.

Report Scope

Market Segmentation

The automated breast ultrasound systems (ABUS) market is segmented by product type, application, end-user, and region.

Based on Product Type Segment, the automated breast ultrasound systems (ABUS) market is divided into Automated Breast Ultrasound System (ABUS), Automated Breast Volume Scanner (ABVS), Automated Whole Breast Ultrasound (AWBU), and others. The Automated Breast Ultrasound System (ABUS) segment is the most dominant due to its ability to provide standardized, operator-independent 3D volumetric imaging that significantly improves detection of small invasive cancers in dense breast tissue while reducing variability and enhancing workflow efficiency in high-volume settings; the second most dominant Automated Breast Volume Scanner (ABVS) segment drives market growth by offering high-resolution diagnostic accuracy and seamless integration with existing mammography workflows, enabling radiologists to achieve earlier and more precise characterization of lesions that supports better patient outcomes and cost-effective screening programs.

Based on Application Segment, the automated breast ultrasound systems (ABUS) market is divided into Breast Cancer Screening, Diagnostic Imaging, Pre-operative Evaluation, and others. The Breast Cancer Screening segment is the most dominant as it serves as the primary supplemental modality to mammography for women with dense breasts and high-risk profiles, delivering comprehensive whole-breast coverage that substantially increases early-stage cancer detection rates and reduces interval cancers; the second most dominant Diagnostic Imaging segment helps drive the market by providing detailed lesion characterization and follow-up capabilities that guide biopsy decisions and treatment planning, thereby improving diagnostic confidence and clinical decision-making across diverse patient populations.

Based on End-User Segment, the automated breast ultrasound systems (ABUS) market is divided into Hospitals, Diagnostic Imaging Centers, Specialty Clinics, and others. The Hospitals segment is the most dominant because these facilities possess the necessary infrastructure, multidisciplinary teams, and high patient throughput required to fully leverage ABUS within comprehensive breast care programs that integrate multiple imaging modalities for optimal outcomes; the second most dominant Diagnostic Imaging Centers segment propels market expansion through their focus on specialized outpatient services, rapid adoption of compact ABUS platforms, and ability to deliver efficient, patient-friendly screening that meets growing demand for convenient and cost-effective breast imaging outside traditional hospital settings.

Based on Region Segment, the automated breast ultrasound systems (ABUS) market is divided into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and others. The North America region is the most dominant owing to its advanced healthcare infrastructure, high awareness levels, supportive reimbursement policies, and strong presence of leading manufacturers that facilitate rapid technology adoption and integration into national screening guidelines; the second most dominant Asia Pacific region drives overall market growth through rising healthcare investments, expanding hospital networks, government-backed awareness campaigns, and increasing incidence of dense breast cases that create substantial demand for supplemental ABUS solutions across both urban and emerging rural markets.

Recent Developments

• In March 2025, GE HealthCare launched the Invenia ABUS Premium system featuring enhanced AI algorithms that deliver faster scan times and improved lesion detection accuracy specifically for dense breast tissue, enabling radiologists to review cases more efficiently while maintaining high diagnostic confidence.
• In February 2024, Candelis introduced an advanced breast imaging workstation optimized for 3D ABUS datasets from multiple vendors, allowing seamless integration of GE, Siemens, and Hitachi systems into existing PACS environments and streamlining multi-vendor workflows in large diagnostic networks.
• In November 2023, GE Healthcare unveiled its MyBreastAI suite that incorporates ABUS data for automated risk assessment and workflow prioritization, significantly reducing radiologist reading time and supporting earlier intervention in high-risk patients across hospital and outpatient settings.
• In July 2024, Delphinus Medical Technologies successfully deployed its SoftVue breast ultrasound tomography system at West Jefferson Medical Center, demonstrating real-world clinical integration of whole-breast tomography that provides radiation-free, comfortable imaging complementary to conventional ABUS platforms.
• In February 2023, iSono Health partnered with Abdul Latif Jameel Health to expand distribution of its portable 3D ABUS scanner across the Middle East and Africa, bringing affordable and mobile breast imaging solutions to underserved regions and accelerating adoption in community health programs.

Regional Analysis

• North America to dominate the global market

North America leads the automated breast ultrasound systems market primarily through the United States, where advanced healthcare infrastructure, widespread implementation of dense breast notification laws, and robust reimbursement frameworks encourage routine supplemental screening with ABUS in both academic medical centers and community hospitals. High breast cancer awareness campaigns, strong collaboration between manufacturers and research institutions, and early regulatory approvals have established the region as an innovation hub where AI-enhanced ABUS platforms are rapidly integrated into standard care pathways for high-risk populations.

The presence of sophisticated PACS systems and highly trained radiologists further supports efficient adoption, while favorable insurance policies reduce financial barriers for patients seeking comprehensive breast imaging. Canada contributes through its publicly funded screening programs that increasingly incorporate ABUS for women with dense breasts, creating consistent demand across provinces and driving technological upgrades in diagnostic facilities nationwide. Overall, the region’s emphasis on preventive care, clinical evidence generation through large-scale trials, and seamless ecosystem of device manufacturers and software developers ensures continued market leadership with superior patient outcomes and operational efficiency.

Europe maintains strong momentum in the automated breast ultrasound systems market with Germany and the United Kingdom serving as primary growth engines due to their well-established national breast screening programs that actively promote supplemental imaging for dense breast tissue. Germany benefits from high healthcare spending, advanced hospital networks, and government subsidies that facilitate widespread installation of ABUS units across both public and private facilities, while radiologists receive specialized training through professional societies to maximize diagnostic accuracy.

The United Kingdom focuses on integrating ABUS into NHS pathways for high-risk patients, supported by technological partnerships that emphasize AI-driven lesion classification and workflow optimization. France, Italy, and Spain contribute through EU-wide initiatives that fund research into non-ionizing imaging technologies and promote cross-border standardization of breast health protocols. The region’s regulatory emphasis on patient safety, combined with rising awareness of breast density implications and collaborative efforts among medical device companies and academic centers, fosters steady expansion and positions Europe as a key innovator in personalized breast cancer screening strategies.

Asia Pacific emerges as the fastest-growing region for automated breast ultrasound systems, led by China, Japan, and India where rapidly aging populations and increasing breast cancer incidence drive urgent demand for advanced, radiation-free imaging solutions. China benefits from massive government investments in healthcare infrastructure, expansion of urban diagnostic centers, and national awareness campaigns that highlight the importance of supplemental screening for dense breasts prevalent among Asian women. Japan leverages its sophisticated medical technology ecosystem and high per-capita healthcare spending to integrate ABUS seamlessly into routine screening at both university hospitals and private clinics, supported by strong local manufacturing capabilities.

India experiences accelerated adoption through public-private partnerships that deploy mobile ABUS units in rural areas and growing private hospital chains that prioritize early detection technologies to serve expanding middle-class populations. South Korea and Australia add momentum through regulatory harmonization and research collaborations that focus on AI applications for dense breast imaging. The region’s combination of demographic shifts, improving reimbursement landscapes, and rising healthcare expenditure creates substantial long-term opportunities for market participants.

Latin America shows promising development in the automated breast ultrasound systems market, spearheaded by Brazil where public health initiatives address the high burden of breast cancer through expanded screening programs that increasingly incorporate ABUS as a cost-effective supplemental tool. Mexico and Argentina contribute through growing private healthcare sectors that invest in modern imaging equipment to meet rising demand from urban populations seeking advanced diagnostic services.

The region benefits from international manufacturer partnerships that provide training programs and localized service support, helping overcome previous infrastructure limitations. Government focus on women’s health and chronic disease management further encourages adoption of operator-independent ultrasound technologies that improve access in underserved communities. Collaborative efforts with global health organizations help standardize protocols and build radiologist expertise, positioning Latin America for sustained growth as economic conditions improve and awareness of dense breast challenges increases across the continent.

The Middle East and Africa region demonstrates emerging potential in the automated breast ultrasound systems market, with Saudi Arabia leading through Vision 2030 healthcare modernization projects that prioritize advanced breast imaging technologies in newly built medical cities and specialized oncology centers. The United Arab Emirates supports growth via its world-class private hospitals that cater to both local and medical tourism patients seeking cutting-edge, non-invasive screening options.

South Africa and other key African nations focus on public-private initiatives that deploy mobile ABUS units to address breast cancer disparities in rural and semi-urban areas where traditional mammography access remains limited. Regional emphasis on capacity building through international training programs helps develop local expertise in interpreting volumetric ultrasound images, while increasing government funding for women’s health programs accelerates technology integration. Strategic partnerships with global manufacturers ensure technology transfer and after-sales support, laying the foundation for gradual yet meaningful market expansion across diverse healthcare landscapes.

Competitive Analysis

The global automated breast ultrasound systems (ABUS) market is dominated by players:

• GE Healthcare
• Siemens Healthineers
• Hologic Inc.
• Koninklijke Philips N.V.
• SonoCine Inc.
• Canon Medical Systems
• Delphinus Medical Technologies
• QT Imaging Inc.
• MetriTrack Inc.
• QView Medical Inc.
• Others

The global automated breast ultrasound systems (ABUS) market is segmented as follows:

By Product Type

• Automated Breast Ultrasound System (ABUS)
• Automated Breast Volume Scanner (ABVS)
• Automated Whole Breast Ultrasound (AWBU)
• Others

By Application

• Breast Cancer Screening
• Diagnostic Imaging
• Pre-operative Evaluation
• Others

By End-User

• Hospitals
• Diagnostic Imaging Centers
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America